Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: An open-label, 8-week, methylphenidate-controlled trial

Clinical Neuropharmacology

Volumn 32, Issue 4, 2009, Pages 179-182

  Cohen Yavin, Iris ^a   Yoran Hegesh, Roni ^a,b   Strous, Rael D ^a,b   Kotler, Moshe ^a,b   Weizman, Abraham ^b,c   Spivak, Baruch ^a,b  

^a NESS ZIONA MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c GEHA MENTAL HEALTH CENTER   (Israel)

Author keywords

ADHD; Methylphenidate; Reboxetine

Indexed keywords

METHYLPHENIDATE; REBOXETINE;

ADOLESCENT; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONSTIPATION; CONTROL GROUP; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; HEADACHE; HUMAN; MALE; OUTCOME ASSESSMENT; OUTPATIENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RATING SCALE; SCHOOL CHILD; STOMACH PAIN; TREATMENT DURATION; TREATMENT INDICATION;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DOPAMINE UPTAKE INHIBITORS; HUMANS; MALE; METHYLPHENIDATE; MORPHOLINES; PATIENT DROPOUTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; TREATMENT OUTCOME;

EID: 68949177129     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318183796d     Document Type: Article

References (17)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: APA; 1994.
2. Spivak B, Vered Y, Yoran-Hegesh R, et al. The influence of three months of methylphenidate treatment on platelet-poor plasma biogenic amines levels in boys with attention deficit hyperactivity disorder. Human Psychopharmacol 2001;16:333-337.
3. Solanto MV Clinical psychopharmacology of ADHD: implications for animal models. Neurosci Biobehav Rev 2000;24:27-30.
4. Elia J, Ambrosini PJ, Rapoport JL. Treatment of ADHD. N Engl J Med 1999;340:780-788.
5. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002;63:50-55.
6. Kratochvil CJ, Heiligenstein JH, Dittman R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002;41:776-784.
7. Spencer TJ, Biederman J, Wilens TE, et al. Novel treatments for ADHD in children. J Clin Psychiatry 2002;63:16-21.
8. Spencer T, Heiligenstein JH, Biederman J, et al. Results from proof-of-concept placebo controlled studies of atomoxetine in children with ADHD. J Clin Psychiatry 2002;63:1140-1147.
9. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in the prefrontal cortex of rat: A potential mechanism for efficacy in ADHD. Neuropsychopharmacology 2002;27(suppl 5):699-671.
10. Versiani M, Cassano G, Perugi G, et al. Reboxetine, a SNRI, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 2002;63:31-37.
11. Kaufman J, Birmaher B, Brent D, et al. Kiddie-SADSVPresent and Lifetime Version. Version 1.0 of October 1996 ed. Pittsburgh, PA: The Department of Psychiatry, University of Pittsburgh School of Medicine; 1996.
12. Conners CK, Russell A, Barkley R. Rating scales and checklists for child psychopharmacology. Psychopharmacol Bull 1985;21: 809-815.
13. Spivak B, Vered Y, Yoran-Hegesh R, et al. Circulatory levels of catecholamines, serotonin and lipids in ADHD. Acta Psychiatr Scand 1999;99:300-304.
14. Pliszka SR, McCracken JT, Maas JW. Catecholamines in ADHD: Current perspectives. J Am Acad Child Adolesc Psychiatry 1996;35: 264-272.
15. Solanto MV Neuropsychopharmacological mechanisms of stimulant drug action in ADHD: A review and integration. Behav Brain Res 1998;94:127-152.
16. Burrows GD, Maguire KP, Norman TR. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: A review. J Clin Psych 1998;59:4-7.
17. Massana J. Reboxetine versus fluoxetine: An overview of efficacy and tolerability. J Clin Psych 1998;59:8-10.